» Articles » PMID: 16436693

Novel Mechanism of Antibiotic Resistance Originating in Vancomycin-intermediate Staphylococcus Aureus

Overview
Specialty Pharmacology
Date 2006 Jan 27
PMID 16436693
Citations 100
Authors
Affiliations
Soon will be listed here.
Abstract

As an aggressive pathogen, Staphylococcus aureus poses a significant public health threat and is becoming increasingly resistant to currently available antibiotics, including vancomycin, the drug of last resort for gram-positive bacterial infections. S. aureus with intermediate levels of resistance to vancomycin (vancomycin-intermediate S. aureus [VISA]) was first identified in 1996. The resistance mechanism of VISA, however, has not yet been clarified. We have previously shown that cell wall thickening is a common feature of VISA, and we have proposed that a thickened cell wall is a phenotypic determinant for vancomycin resistance in VISA (L. Cui, X. Ma, K. Sato, et al., J. Clin. Microbiol. 41:5-14, 2003). Here we show the occurrence of an anomalous diffusion of vancomycin through the VISA cell wall, which is caused by clogging of the cell wall with vancomycin itself. A series of experiments demonstrates that the thickened cell wall of VISA could protect ongoing peptidoglycan biosynthesis in the cytoplasmic membrane from vancomycin inhibition, allowing the cells to continue producing nascent cell wall peptidoglycan and thus making the cells resistant to vancomycin. We conclude that the cooperative effect of the clogging and cell wall thickening enables VISA to prevent vancomycin from reaching its true target in the cytoplasmic membrane, exhibiting a new class of antibiotic resistance in gram-positive pathogens.

Citing Articles

In Vitro Antimicrobial Efficacy Assessment of Ethanolic, Aqueous, and Dual Solvent Extracts of Mushroom : Genomic and Morphological Analysis.

Akamu E, Merrills L, Williams Z, Justice B, Iloghalu U, Williams V Antibiotics (Basel). 2025; 13(12.

PMID: 39766499 PMC: 11672760. DOI: 10.3390/antibiotics13121109.


Muropeptides and muropeptide transporters impact on host immune response.

Orsini Delgado M, Gamelas Magalhaes J, Morra R, Cultrone A Gut Microbes. 2024; 16(1):2418412.

PMID: 39439228 PMC: 11509177. DOI: 10.1080/19490976.2024.2418412.


Effects of Vancomycin Subtherapeutic Concentration on Staphylococcus aureus Isolated from Hemodialysis Patients with Low Serum Trough Concentrations.

Chagas R, Silva C, de Cassia Teixeira Birro J, Dos Santos K Curr Microbiol. 2024; 81(2):65.

PMID: 38231442 DOI: 10.1007/s00284-023-03588-3.


Resistance phenotype and genetic features of a heterogeneous vancomycin intermediate-resistant Staphylococcus aureus strain from an immunocompromised patient.

Cheng X, Wang Y, Ma J, Ma L, Sun W, Su J Braz J Microbiol. 2023; 55(1):323-332.

PMID: 38057692 PMC: 10920550. DOI: 10.1007/s42770-023-01192-y.


Comparative proteomic analysis of vancomycin-sensitive and vancomycin-intermediate resistant Staphylococcus aureus.

Hu J, Han X, Ma X, Chen X, Zhou Z, Peng P Eur J Clin Microbiol Infect Dis. 2023; 43(1):139-153.

PMID: 37985551 DOI: 10.1007/s10096-023-04709-3.


References
1.
Komatsuzawa H, Ohta K, Yamada S, Ehlert K, Labischinski H, Kajimura J . Increased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant. Antimicrob Agents Chemother. 2001; 46(1):75-81. PMC: 126989. DOI: 10.1128/AAC.46.1.75-81.2002. View

2.
Verwer R, Beachey E, Keck W, Stoub A, Poldermans J . Oriented fragmentation of Escherichia coli sacculi by sonication. J Bacteriol. 1980; 141(1):327-32. PMC: 293591. DOI: 10.1128/jb.141.1.327-332.1980. View

3.
Lu J, Lee S, Hwa S, Yang A . Septic arthritis caused by vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol. 2005; 43(8):4156-8. PMC: 1233910. DOI: 10.1128/JCM.43.8.4156-4158.2005. View

4.
Sieradzki K, Tomasz A . Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol. 1997; 179(8):2557-66. PMC: 179004. DOI: 10.1128/jb.179.8.2557-2566.1997. View

5.
Sieradzki K, Pinho M, Tomasz A . Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus. J Biol Chem. 1999; 274(27):18942-6. DOI: 10.1074/jbc.274.27.18942. View